Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Br J Clin Pharmacol ; 85(2): 377-384, 2019 02.
Artigo em Inglês | MEDLINE | ID: mdl-30378151

RESUMO

AIMS: Nitroglycerin (or glyceryl trinitrate, GTN) has been long considered an endothelium-independent vasodilator because GTN vasodilation is intact in the absence of the endothelium and in the presence of endothelial dysfunction. However, in animal and in vitro models, GTN has been shown to stimulate the release of certain endothelium-derived vasodilators such as nitric oxide (NO) and prostacyclin (PGI2 ). In addition, chronic GTN therapy leads to endothelial dysfunction. In this series of experiments, we explored how GTN might interact with the vascular endothelium in normal humans, without cardiovascular disease or risk factors associated with abnormalities in vascular function. METHODS: We examined the effect of inhibition of NO, PGI2 , and epoxyeicosatrienoic acids (EETs, a class of endothelium-derived hyperpolarizing factor) on GTN-mediated vasodilation. We measured arterial blood flow responses to brachial artery infusions of GTN in the absence and presence of L-NMMA (n = 13), ketorolac (n = 14) and fluconazole (n = 16), which are inhibitors of endothelium-derived NO, PGI2 and EETs, respectively, in healthy volunteers. RESULTS: Our results demonstrate that inhibition of endothelium-dependent vasodilator mechanisms does not alter forearm resistance vessel responses to GTN. CONCLUSION: We conclude that GTN-mediated dilation of forearm resistance vessels is largely independent of vascular endothelium.


Assuntos
Endotélio Vascular/efeitos dos fármacos , Nitroglicerina/farmacologia , Fluxo Sanguíneo Regional/efeitos dos fármacos , Vasodilatação/efeitos dos fármacos , Vasodilatadores/farmacologia , Adolescente , Adulto , Animais , Endotélio Vascular/metabolismo , Epoprostenol/antagonistas & inibidores , Epoprostenol/metabolismo , Feminino , Antebraço/irrigação sanguínea , Voluntários Saudáveis , Humanos , Masculino , Óxido Nítrico/antagonistas & inibidores , Óxido Nítrico/metabolismo , Projetos Piloto , Resistência Vascular/efeitos dos fármacos , Adulto Jovem
2.
J Cardiovasc Pharmacol ; 73(6): 359-364, 2019 06.
Artigo em Inglês | MEDLINE | ID: mdl-31162244

RESUMO

The mechanism of the bioactivation of nitroglycerin has long been controversial, with a number of suggested enzymatic pathways. More recently, aldehyde dehydrogenase-2 (ALDH-2) has been reported as the important enzyme involved in the bioactivation of nitroglycerin at therapeutically relevant concentrations. Other previously described enzyme systems can also bioactivate nitroglycerin, but only at concentrations, which are significantly higher than achieved in clinical practice. This study investigated the vascular response to nitroglycerin given over a wide range of concentrations in subjects with and without the ALDH-2 Glu504Lys polymorphism, a common genetic variant that greatly reduces the activity of ALDH-2 (n = 10 in both groups). Forearm blood flow (FBF) responses to a brachial artery infusion of nitroglycerin were assessed using venous occlusion plethysmography. Intra-arterial infusion of nitroglycerin caused a significant increase in FBF beginning at 0.464 µg/min with increasing responses seen in both groups at all infusion rates. However, there were no differences in the FBF responses to nitroglycerin in those with and without the ALDH-2 polymorphism, suggesting that ALDH-2 is not solely responsible for the bioactivation of nitroglycerin at either low (therapeutically relevant) or high concentrations of nitroglycerin.


Assuntos
Aldeído-Desidrogenase Mitocondrial/metabolismo , Artéria Braquial/efeitos dos fármacos , Antebraço/irrigação sanguínea , Mitocôndrias/efeitos dos fármacos , Nitroglicerina/administração & dosagem , Vasodilatação/efeitos dos fármacos , Vasodilatadores/administração & dosagem , Ativação Metabólica , Adolescente , Adulto , Aldeído-Desidrogenase Mitocondrial/genética , Pressão Arterial/efeitos dos fármacos , Artéria Braquial/enzimologia , Relação Dose-Resposta a Droga , Feminino , Frequência Cardíaca/efeitos dos fármacos , Humanos , Infusões Intra-Arteriais , Masculino , Mitocôndrias/enzimologia , Nitroglicerina/metabolismo , Polimorfismo Genético , Distribuição Aleatória , Transdução de Sinais , Vasodilatadores/metabolismo , Adulto Jovem
3.
Can J Physiol Pharmacol ; 90(8): 1075-85, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22783820

RESUMO

Metabolic syndrome (MS) is a combination of medical disorders that increase the risk of developing cardiovascular disease and diabetes. MS is associated with obesity, increased blood pressure, hyperlipidemia, and hyperglycemia. This study was designed to investigate the pharmacological profile of phentolamine, a nonselective α adrenergic receptor antagonist, in the prevention of increased blood pressure in fructose-fed rats. Phentolamine prevented the fructose-induced increase in systolic blood pressure without affecting insulin sensitivity and major metabolic parameters. The levels of plasma noradrenaline and angiotensin II, 2 proposed contributors to the development of fructose-induced elevated blood pressure, were examined. Neither noradrenaline nor angiotensin II levels were affected by phentolamine treatment. Since overproduction of nitric oxide has been shown to lead to an elevation in peroxynitrite, the role of oxidative stress, a proposed mechanism of fructose-induced elevated blood pressure and insulin resistance, was examined by measuring plasma levels of total nitrate/nitrite. Plasma nitrate/nitrite was significantly elevated in all fructose-fed animals, regardless of treatment with phentolamine. Another proposed contributor toward fructose-induced MS is an elevation in uric acid levels. In this experiment, plasma levels of uric acid were found to be increased by dietary fructose and were unaffected by phentolamine treatment.


Assuntos
Antagonistas Adrenérgicos alfa/uso terapêutico , Hipertensão/tratamento farmacológico , Síndrome Metabólica/tratamento farmacológico , Fentolamina/uso terapêutico , Antagonistas Adrenérgicos alfa/farmacologia , Angiotensina II/sangue , Animais , Glicemia/efeitos dos fármacos , Pressão Sanguínea/efeitos dos fármacos , Pressão Sanguínea/fisiologia , Modelos Animais de Doenças , Frutose , Hipertensão/sangue , Hipertensão/fisiopatologia , Insulina/sangue , Masculino , Síndrome Metabólica/sangue , Síndrome Metabólica/induzido quimicamente , Síndrome Metabólica/fisiopatologia , Norepinefrina/sangue , Fentolamina/farmacologia , Ratos , Ratos Wistar , Espécies Reativas de Nitrogênio/sangue , Ácido Úrico/sangue
4.
Vascul Pharmacol ; 71: 159-65, 2015 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-25869511

RESUMO

The 3-hydroxy-3-methylglutaryl coenzyme A (HMG Co-A) reductase inhibitors have preconditioning effects involving up-regulation of cyclooxygenase (COX)-2. We investigated the effect of selective and non-selective COX inhibition on rosuvastatin-mediated protection against ischemia-reperfusion (IR)-induced endothelial dysfunction in the human forearm. Healthy volunteers (n=66) were allocated to placebo, acetylsalicylic acid (ASA) 81mg daily, ASA 325mg daily, celecoxib 200mg twice daily or 400mg ibuprofen four times daily, each administered for 5 to 7days. On the last day of study drug therapy, subjects received a single dose of 40mg rosuvastatin. Twenty-four hours later flow-mediated dilation (FMD) of the radial artery was evaluated before and after IR. In the placebo group, FMD was similar before and after IR (8.1±1.0 vs 7.2±0.8%; P=NS) indicating a significant protective effect of rosuvastatin. There was also no effect of IR on FMD in the ASA 81mg group (6.7±0.6 vs 6.1±0.7%; P=NS). In contrast, following IR there was a significant decrease in FMD in the ASA 325mg group (7.2±0.8 vs 3.3±0.7%, P<0.001), the celecoxib group (7.3±1.5 vs 2.6±1.5%, P<0.01) as well as the ibuprofen group (6.8±0.7 vs 2.6±0.8%; P<0.01). Therefore, nonselective COX inhibition with ASA 325mg and ibuprofen completely inhibit the protective effects of rosuvastatin in the setting of IR injury, as does therapy with the specific COX-2 antagonist celecoxib. In contrast, therapy with low dose ASA (81mg daily) does not have such inhibitory effects.


Assuntos
Inibidores de Ciclo-Oxigenase/administração & dosagem , Endotélio Vascular/efeitos dos fármacos , Traumatismo por Reperfusão/prevenção & controle , Rosuvastatina Cálcica/administração & dosagem , Vasodilatação/efeitos dos fármacos , Adolescente , Adulto , Velocidade do Fluxo Sanguíneo/efeitos dos fármacos , Velocidade do Fluxo Sanguíneo/fisiologia , Pressão Sanguínea/efeitos dos fármacos , Pressão Sanguínea/fisiologia , Quimioterapia Combinada , Endotélio Vascular/fisiologia , Frequência Cardíaca/efeitos dos fármacos , Frequência Cardíaca/fisiologia , Humanos , Masculino , Traumatismo por Reperfusão/fisiopatologia , Método Simples-Cego , Vasodilatação/fisiologia , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA